A clinical imaging Study of the changes in [18F]F-AraG uptake following Radiotherapy in Non-small cell lung cancer.

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517960-45-00

Enrollment

Registered

2024-10-02

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Esophageal Cancer, Melanoma, Non-small Cell Lung Cancer

Brief summary

To assess the relative change in uptake of [18F]F-AraG in tumor lesions on anti-PD-1 treatment. i. To define tracer uptake in all tumor lesions and lymphoid organs (lymph nodes, spleen) per [ 18F]F-AraG PET scan using the optimized simplified uptake parameter (SUV, TBR, TPR). ii. To assess the changes in uptake between baseline and after 1 and 3 weeks post-RT, respectively.

Interventions

DRUGNELARABINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To assess the relative change in uptake of [18F]F-AraG in tumor lesions on anti-PD-1 treatment. i. To define tracer uptake in all tumor lesions and lymphoid organs (lymph nodes, spleen) per [ 18F]F-AraG PET scan using the optimized simplified uptake parameter (SUV, TBR, TPR). ii. To assess the changes in uptake between baseline and after 1 and 3 weeks post-RT, respectively.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026